Interleukin-20 receptor type II heterodimer (IL-20R type II)

The Interleukin-20 (IL-20) receptor type II heterodimer is a class II cytokine receptor complex composed of the interleukin-22 receptor subunit alpha 1 (IL-22RA1) and the interleukin-20 receptor subunit beta (IL-20RB) [Wikipedia, NIH]. This receptor is primarily expressed on non-hematopoietic cells, particularly epithelial cells in the skin, lungs, and gastrointestinal tract, where it mediates the effects of the cytokines IL-20 and IL-24 [NIH, ResearchGate]. Upon activation by these ligands, the receptor triggers the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, specifically activating STAT3 to promote cell proliferation, tissue remodeling, and pro-inflammatory gene expression [NIH, MedChemExpress]. The IL-20 receptor type II plays a significant role in the pathogenesis of chronic inflammatory diseases such as psoriasis and atopic dermatitis, as well as in certain cancers and cardiovascular diseases [NIH, PatSnap]. Therapeutic targeting of this receptor, notably through the use of monoclonal antibodies like temtokibart that antagonize the IL-22RA1 subunit, is being explored to inhibit the pathological signaling of IL-20, IL-24, and IL-22 in inflammatory conditions [PatSnap, ClinicalTrialsArena]. However, pharmacological modulation of this target requires careful consideration of potential safety concerns, including increased susceptibility to infections and impacts on metabolic homeostasis [NIH, Frontiers].

Other names

IL-22RA1/IL-20RB complexIL-22R1/IL-20R2 complexInterleukin-20 receptor type 2IL-22R1/IL-20R2 heterodimer

Antagonism of the receptor subunits (specifically IL-22RA1) to block the signaling of IL-20, IL-24, and IL-22 cytokines [PatSnap, ClinicalTrialsArena].